A GFR of 23 mL/min/1.73 m² corresponds to Stage 4 Chronic Kidney Disease
This represents severe reduction in kidney function and requires urgent nephrology referral and preparation for renal replacement therapy.
CKD Staging Classification
Based on the internationally accepted KDIGO classification system, chronic kidney disease is staged according to glomerular filtration rate 1, 2:
- Stage 1: GFR ≥90 mL/min/1.73 m² (with kidney damage markers)
- Stage 2: GFR 60-89 mL/min/1.73 m² (with kidney damage markers)
- Stage 3a: GFR 45-59 mL/min/1.73 m²
- Stage 3b: GFR 30-44 mL/min/1.73 m²
- Stage 4: GFR 15-29 mL/min/1.73 m² (severe reduction)
- Stage 5: GFR <15 mL/min/1.73 m² or dialysis-dependent (kidney failure)
Your GFR of 23 mL/min/1.73 m² falls squarely within Stage 4 CKD 1, 3, 2.
Critical Clinical Implications at Stage 4
Immediate Actions Required
Nephrology referral is mandatory at this stage 4. The guidelines specifically recommend consultation when eGFR falls below 30 mL/min/1.73 m², as this represents advanced kidney disease requiring discussion of renal replacement therapy 4.
Planning for Renal Replacement Therapy
At Stage 4, you should begin planning for dialysis access or preemptive kidney transplantation. The guidelines recommend considering planning when GFR is <15-20 mL/min/1.73 m² or when the risk of requiring kidney replacement therapy exceeds 40% over 2 years 5. With a GFR of 23, you are approaching this threshold and need proactive preparation.
Expected Complications at This Stage
Stage 4 CKD carries significant risk for multiple complications 3, 2:
- Anemia: Prevalence of hemoglobin <110 g/L reaches 42% when GFR drops below 30 6
- Metabolic bone disease: Elevated phosphate (15% prevalence) and calcium abnormalities (8% prevalence) 6
- Metabolic acidosis: Bicarbonate <23 mmol/L occurs in 33% of patients 6
- Cardiovascular disease: Dramatically increased risk compared to earlier stages 2
- Uremic symptoms: May begin to manifest as GFR approaches 15 mL/min/1.73 m²
Essential Management at Stage 4
Pharmacotherapy priorities 7, 4:
- SGLT2 inhibitors if eGFR ≥20 mL/min/1.73 m² (can continue even if GFR drops below 20 once started) 7
- ACE inhibitors or ARBs for blood pressure control and proteinuria management 1
- Finerenone (nonsteroidal mineralocorticoid receptor antagonist) if diabetic kidney disease is present 4
- Statins for cardiovascular risk reduction 8
Blood pressure target: Aim for systolic BP of 120 mmHg when tolerable 9
- Protein restriction to approximately 0.8 g/kg/day
- Sodium limitation to 2 g/day
Monitoring requirements: More frequent assessment of kidney function, electrolytes (especially potassium), hemoglobin, calcium, phosphate, and bicarbonate 3, 6.
Common Pitfalls to Avoid
Do not rely on serum creatinine alone. Studies show that 62.5% of patients with Stage 3-4 CKD have normal serum creatinine concentrations 10, 11. The calculated GFR is far more accurate for assessing true kidney function.
Do not delay nephrology referral. Stage 4 CKD requires specialist input for optimal management of complications and timely preparation for renal replacement therapy 4.
Nephrotoxin stewardship is critical 8. Avoid NSAIDs, ensure appropriate dose adjustments for all renally cleared medications, and educate on sick day medication management to prevent acute-on-chronic kidney injury.
Prognosis and Risk Stratification
The risk stratum depends not only on GFR but also on albuminuria 7. With GFR 15-29 mL/min/1.73 m², you are classified as:
- High risk if albuminuria is <30 mg/mmol
- Very high risk if albuminuria is ≥30 mg/mmol
This risk classification determines the intensity of monitoring and treatment 7.